Novogen Ltd. (ADR) is Today's Focus Stock on MicroStockProfit.com
March 29 2011 - 6:50AM
MicroStockProfit.com announces an investment report featuring
Novogen Ltd. (ADR) (Nasdaq:NVGN). The report includes financial,
comparative and investment analyses, and industry information you
need to know to make an educated investment decision.
The full report is available at:
www.microstockprofit.com/lp/NVGN
Novogen Ltd. (NVGN) is an Australia-based biotechnology company
engaged in pharmaceutical research and development, as well as
marketing of consumer healthcare products. The Company is primarily
involved in the development of prescription drugs based on the
isoflavonoid technology platform. The Company is structured into
four divisions: Pharmaceutical division, which develops a portfolio
of prescription drugs; Consumer Health division, which develops a
range of non-prescription products; Marshall Edwards Inc., which
focuses on the development of oncology drugs, and Glycotex Inc.,
which focuses on seeking funds to enable to complete and extend the
clinical development program. Within its divisions the Company also
conducts oncology program, cardiovascular program, dermatological
program and anti-inflammatory program.
This newsletter has been helping traders make great investment
decisions on OBCI; click here for a 25% discount offer.
In the report, the analyst notes:
"Shares of NVGN set a new 52-week high of $2.97 Monday, before
settling the day at $2.17, an increase of 104.72% for the
day. About 5.40 million shares changed hands during the
session, well above the stock's 10-day average volume of 102.47K.
NVGN is currently trading above its 50-day moving average of $0.83
and 200-day moving average of $0.65. Market capitalization
currently stands at $44.79 million and it has 20.64 million
outstanding shares."
"NVGN's subsidiary Marshall Edwards Inc. (MSHL) last week
announced the publication of results from a phase II clinical trial
of intravenous phenoxodiol in combination with cisplatin in women
with platinum-resistant ovarian cancer. The publication is now
available on the International Journal of Gynecological Cancer Web
site and scheduled to print in the May issue of the journal."
To read the entire report visit:
www.microstockprofit.com/lp/NVGN
See what investors are saying about NVGN at
http://www.stockhideout.com
Get breaking news on NVGN at http://thestockmarketwatch.com/
MicroStockProfit.com is a small-cap research and investment
commentary provider. MicroStockProfit.com strives to provide a
balanced view of many promising small-cap companies that would
otherwise fall under the radar of the typical Wall Street investor.
We provide investors with an excellent first step in their research
and due diligence by providing daily trading ideas, and
consolidating the public information available on them. For more
information on MicroStockProfit please visit:
http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and
nothing contained in any materials should be construed as a
recommendation to buy or sell any securities. MicroStockProfit.com
is a Web site wholly owned by BlueWave Advisors, LLC. Neither
MicroStockProfit.com nor its affiliates have a beneficial interest
in the mentioned company; nor have they received compensation of
any kind for any of the companies listed in this communication.
Please read our report and visit our Web site,
MicroStockProfit.com, for complete risks and disclosures.
CONTACT: Brian Johnson
info@microstockprofit.com
1-888-307-2850
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024